Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 175 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tuberculosis Clear all
Completed No phase listed Observational Results available

Evaluation of the QuantiFERON-TB Test.

NCT02253537
View directory record Official record
Conditions
Tuberculosis
Interventions
CST001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Not applicable Interventional Results available

Brief Educational Video for Patients Prescribed LTBI Treatment

NCT05412212
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
LTBI video intervention
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the QuantiFERON-TB Test.

NCT02256839
View directory record Official record
Conditions
Tuberculosis
Interventions
CST_001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 4 Interventional Results available

Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis

NCT01960257
View directory record Official record
Conditions
Tuberculosis
Interventions
Digital Health Feedback System, SOC DOT
Device · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

NCT02534727
View directory record Official record
Conditions
Tuberculosis, Non-Tuberculosis Mycobacteria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Withdrawn No phase listed Observational

Tuberculosis Research Blood Bank

NCT00212498
View directory record Official record
Conditions
Tuberculosis
Interventions
Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Jul 20, 2026, 7:20 PM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

NCT03510468
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jul 20, 2026, 7:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
lopinavir/ritonavir, rifabutin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational

TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment

NCT00023439
View directory record Official record
Conditions
Tuberculosis
Interventions
Nucleic Acid Amplification Methods for diagnosis
Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

NCT03199313
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Sutezolid, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

NCT02508376
View directory record Official record
Conditions
Tuberculosis
Interventions
AP10-602, GLA-SE, ID93
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 20, 2026, 7:20 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Cabotegravir (CAB), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)

NCT01830439
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824 200mg, PA-824 50mg
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational

Immune Response to Mycobacterium Tuberculosis Infection

NCT00257907
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 3 Interventional

Nutrition, Immunology and Epidemiology of Tuberculosis

NCT00197704
View directory record Official record
Conditions
Tuberculosis
Interventions
Multivitamins, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Not applicable Interventional

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

NCT00023387
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, 25-desacetyl Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

NCT03722472
View directory record Official record
Conditions
Pulmonary TB
Interventions
ID93 + GLA-SE
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations

NCT01167452
View directory record Official record
Conditions
Obesity, Pharmacokinetics, MRSA, Tuberculosis, PCP
Interventions
Sulfamethoxazole/trimethoprim
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 20, 2026, 7:20 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of SQ109 on QTc Interval in Healthy Subjects

NCT01874314
View directory record Official record
Conditions
Tuberculosis
Interventions
SQ109, SQ109 Placebo, Moxifloxacin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Jul 20, 2026, 7:20 PM EDT
Recruiting No phase listed Observational

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

NCT04052022
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

NCT00871949
View directory record Official record
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Jul 20, 2026, 7:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

NCT00460759
View directory record Official record
Conditions
Mycobacterium Tuberculosis
Interventions
Moxifloxacin, Rifapentine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jul 20, 2026, 7:20 PM EDT